Buy Strides Arcolab on correction; can touch Rs 400 mark: Ashit Suri

ET Now caught up with Ashit Suri, Fundamental Research Analyst, JV Capital Services, to find out his take on the midcap pharma space.

What are you recommending your clients from the midcap pharma space?

I have been suggesting a buy on Strides Arcolab from the Rs 270 levels. The stock has done very well and it has been in regular news flow, which has dragged it to highs of around Rs 335-340 levels today. This stock is expected to do well in the future. It would be a good idea to buy it on correction at Rs 310-315 on an accumulate basis. For people who have been buying on our suggestions, we have been recommending partial profit bookings at every high, so that's the story the stock has the capability to reach the Rs 400 mark over the medium term and we are very positive on the stock.